17/09/20 -"Our EPS estimates move higher, reflecting the strong demand for bioprocessing products from COVID-19-related drug/vaccine manufacturers. Given Sartorius is working with nearly 80% of potential ..."
Pages
65
Language
English
Published on
17/09/20
You may also be interested by these reports :
24/04/24
Getinge reported a mixed set of results, missing top-line estimates marginally but beating on profit and order intake. Investors cheered the latter, ...
23/04/24
We have factored the 2023 actual figures into our model ahead of the availability of the annual report and more detailed information. The difference ...
22/04/24
Sartorius Stedim reported softer-than-expected Q1 24 numbers, missing the consensus by 5.7%/3.4% on the top line/bottom line, respectively. The ...
22/04/24
Sartorius reported softer-than-expected Q1 24 numbers, missing the consensus by 5.4% on the top line, but beating (+2.4%) on the bottom line. The ...